JPMorgan Chase & Co (WAR:JPM)
zł 1038.4 0 (0%) Market Cap: 2.76 Til Enterprise Value: 2.96 Til PE Ratio: 13.77 PB Ratio: 2.15 GF Score: 79/100

Enanta Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:45 AM Transcript

Jan 10, 2024 / 05:45PM GMT
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Okay. Great. Good morning. I'm Eric Joseph, senior biotech analyst with JPMorgan, and our next presenting company is Enanta Pharmaceuticals. Presenting on behalf of the company is CEO, Jay Luly. There's a Q&A after the presentation. We'll bring mics around for those who have questions and folks tuning in via webcast, feel free to submit questions via the portal.

With that, Jay, thanks for joining us.

Jay R. Luly
Enanta Pharmaceuticals, Inc. - President, CEO & Director

Thanks, Eric. Before I begin, I want to remind you that I'll be making some forward-looking statements. And for a summary of the risks associated with these statements, please see our filings on sec.gov and on our website. For those of you less familiar with Enanta, we're a company that has sort of a legacy in virology. We're working on multiple different viral targets. More recently, have expanded into respiratory viruses, including RSV and SARS-CoV-2. And today, I will also be talking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot